Drug Trial Radar · NCT05103358
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Mar 10, 2022
Primary completion
Dec 23, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Aadi Bioscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Conditions
- Tumor
- Tumor, Solid
- Metastasis
- Metastatic Cancer
- Cancer
- Cancer Metastatic
- Tumors
- Neoplasms
- Neoplasm Metastasis
- Solid Tumor
- Advanced Solid Tumor
- Advanced Cancer
- Malignant Solid Tumor
- Malignant Solid Neoplasm
- Malignant Neoplasm
- Malignant Tumor
- TSC
- TSC1
- TSC2
- Metastatic Solid Tumor
- Metastatic Neoplasm
Interventions
nab-sirolimusDrug
Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.
Locations
166 sites in 3 countries. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
Southern Cancer Center
Mobile, Alabama
Arizona Oncology Associates
Goodyear, Arizona
Honor Health
Phoenix, Arizona
Arizona Oncology Associates
Prescott Valley, Arizona
Yuma Regional Medical Center
Yuma, Arizona
PCR Oncology
Arroyo Grande, California
Nextgen Oncology
Beverly Hills, California
City of Hope
Duarte, California
Providence Medical Foundation (Fullerton)
Fullerton, California
MemorialCare
Long Beach, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
UCLA - Jonsson Comprehensive Cancer Center
Los Angeles, California
Providence Medical Foundation (Napa)
Napa, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Sharp HealthCare
San Diego, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Ridley-Tree Cancer Center
Santa Barbara, California
Sarcoma Oncology Research Center
Santa Monica, California
Providence Medical Foundation
Santa Rosa, California
Stanford Cancer Center
Stanford, California
The Oncology Institute of Hope & Innovation
Whittier, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Rocky Mountain Cancer Centers (Williams St)
Denver, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
Rocky Mountain Cancer Centers
Lakewood, Colorado
Rocky Mountain Cancer Centers
Littleton, Colorado
Rocky Mountain Cancer Centers
Lone Tree, Colorado
Rocky Mountain Cancer Centers
Longmont, Colorado
Rocky Mountain Cancer Centers
Pueblo, Colorado
Rocky Mountain Cancer Centers
Thornton, Colorado
Hartford Healthcare
Hartford, Connecticut
Eastern Connecticut Hematology and Oncology
Norwich, Connecticut
Florida Cancer Specialists - North Division
Altamonte Springs, Florida
Florida Cancer Specialists - South Division
Bonita Springs, Florida
Florida Cancer Specialists - South Division
Bradenton, Florida
Florida Cancer Specialists - South Division
Bradenton, Florida
Florida Cancer Specialists - North Division
Brandon, Florida
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.